Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment
1993; Wiley; Volume: 43; Issue: 2 Linguagem: Inglês
10.3322/canjclin.43.2.93
ISSN1542-4863
AutoresElizabeth Abel, Gary S. Wood, Richard T. Hoppe,
Tópico(s)Lymphoma Diagnosis and Treatment
ResumoCA: A Cancer Journal for CliniciansVolume 43, Issue 2 p. 93-115 ArticleFree Access Mycosis fungoides: Clinical and histologic features, staging, evaluation, and approach to treatment Elizabeth A. Abel MD, Elizabeth A. Abel MD Clinical Associate Professor of Dermatology in the Department of Dermatology at Stanford University School of Medicine in Stanford, CaliforniaSearch for more papers by this authorGary S. Wood MD, Gary S. Wood MD Associate Professor of Dermatology in the Departments of Dermatology and Pathology at Case Western Reserve University and Veterans Administration Medical Center in Cleveland, OhioSearch for more papers by this authorRichard T. Hoppe MD, Richard T. Hoppe MD Professor of Radiation Oncology in the Department of Radiation Oncology at Stanford University School of Medicine in Stanford, CaliforniaSearch for more papers by this author Elizabeth A. Abel MD, Elizabeth A. Abel MD Clinical Associate Professor of Dermatology in the Department of Dermatology at Stanford University School of Medicine in Stanford, CaliforniaSearch for more papers by this authorGary S. Wood MD, Gary S. Wood MD Associate Professor of Dermatology in the Departments of Dermatology and Pathology at Case Western Reserve University and Veterans Administration Medical Center in Cleveland, OhioSearch for more papers by this authorRichard T. Hoppe MD, Richard T. Hoppe MD Professor of Radiation Oncology in the Department of Radiation Oncology at Stanford University School of Medicine in Stanford, CaliforniaSearch for more papers by this author First published: March/April 1993 https://doi.org/10.3322/canjclin.43.2.93Citations: 49AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Edelson RL: Cutaneous T-cell lymphoma: Mycosis fungoides, Sézary syndrome and other variants. J Am Acad Dermatol 1980; 2: 89– 106. 2 Abel EA: Clinical features of cutaneous T-cell lymphoma. Dermatologic Clinics 1985; 3: 647– 664. 3 Kaye FJ, Bunn PA, Steinberg SM, et al: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. New Engl J Med 1989; 321: 1784– 1790. 4 Kaye FJ, Bunn PA, Steinberg SM, et al: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784– 1790. 5 Weinstock MA, Horm JW: Mycosis fungoides in the United States: Increasing incidence and descriptive epidemiology. JAMA 1988; 260: 42– 46. 6 Peters MS, Thibodeau SN, White JW, Winkelmann RK: Mycosis fungoides in children and adolescents. J Am Acad Dermatol 1990; 22: 1011– 1018. 7 Burns MK, Ellis CN, Cooper KD: Mycosis fungoide type cutaneous T-cell Lymphoma arising before 30 years of age. J Am Acad Dermatol 1992; 27: 974– 978. 8 Greene MH, Dalager NA, Lamberg SI: Mycosis fungoides: Epidemiologic observations. Cancer Treat Rep 1979; 63: 597– 606. 9 Tan RSH, Butterworth CM, McLaughlin H, et al: Mycosis fungoides: A disease of antigen persistence. Br J Dermatol 1974; 91: 607– 616. 10 Rowden G, Phillips TM, Lewis MG, Wilkinson RD: Target role of Langerhans cells in mycosis fungoides: Transmission and immunoelectron microscopic studies. J Cutan Pathol 1979; 6: 364– 382. 11 Tuyp E, Burgoyne A, Aitchison T, Mackie R: A case-control study of possible causative factors in mycosis fungoides. Arch Dermatol 1987; 123: 196– 200. 12 Whittemore AS, Holly EA, Lee IM, et al: Mycosis fungoides in relation to environmental exposures and immune response: A case-control study. J Natl Cancer Inst 1989; 81: 1560– 1567. 13 MacKie RM: Initial event in mycosis fungoides of the skin is viral infection of epidermal Langerhans cells. Lancet 1981; 2: 283– 285. 14 Solomon AR: Retroviruses and lymphoproliferative disease: Dermatologic Clinics 1985: 3: 615– 627. 15 Broder S, Bunn PA, Jaffe ES, et al: T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med 1984; 100: 543– 557. 16 Myskowsky PL: Cutaneous T-cell lymphoma in patients with human immunodeficiency virus infections. Arch Dermatol 1991; 8: 73– 81. 17 Lambert WC: Premycotic eruptions. Dermatologic Clinics 1985; 3: 647– 664. 18 Samman PD: Mycosis fungoides and other cutaneous reticuloses. Clin Exp Dermatol 1976; 1: 197– 214. 19 Epstein EH Jr, Levin DL, Croft JD Jr, Lutzner MA: Mycosis fungoides: Survival, prognostic features, response to therapy and autopsy findings. Medicine 1972; 51: 61– 72. 20 Alibert JLM: Tableau du plan fongoide: Déscription des maladies de la peau observée a l'hopital St. Louis, et exposition des meilleures méthods suivies pour leur traitement. Paris, Barrios l'Ainé et Files, 1806. 21 Lutzner MA, Jordan HW: The ultrastructure of an abnormal cell in Sézary's syndrome. Blood 1968; 31: 719– 726. 22 Haynes BF, Metzgar RS, Minna JD, et al: Phenotype characterization of cutaneous T-cell lymphoma: Use of monoclonal antibodies to compare with other malignant T cells. N Engl J Med 1981; 304: 1319– 1323. 23 Wood GS, Burke JS, Horning S, et al: The immunologic and clinicopathologic heterogeneity of cutaneous lymphomas other than mycosis fungoides. Blood 1983; 62: 464– 472. 24 Oliver GF, Winkelmann RK: Unilesional mycosis fungoides: A distinct entity. J Am Acad Dermatol 1989; 20: 63– 70. 25 Videl E, Brocq L: Étude sur le mycosis fungoides. Fr Med 1885;2:946,967,969,983,993,1005,1019. 26 LeBoit PE: Variants of mycosis fungoides and related cutaneous T-cell lymphomas. Seminars in Diagnostic Pathology 1991; 8: 73– 81. 27 Wood GS, Matthews MJ: Diagnosis of malignant lymphoproliferative disorders in the skin, in Jaffe ES (ed): Surgical Pathology of the Lymph Nodes and Related Organs, ed 2. Philadelphia, WB Saunders Co, in press. 28 Salhany KE, Cousar JB, Greer JP, et al: Transformation of cutaneous T-cell lymphoma to large cell lymphoma: A clinicopathologic and immunologic study. Am J Pathol 1988; 132: 265– 277. 29 Wieselthier JS, Koh HK: Sézary syndrome: Diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 1990; 22: 381– 401. 30 Prunieras M: Le syndrome et la cellule de Sézary. Dermatologica 1978; 157: 371– 376. 31 Woringer F, Kolopp P: Lesion erythematosquameuse polycyclique de l'avant-bras depuis 6 ans chez un garconnet de 13 ans. Ann Dermatol Syphil 1939; 10: 945– 958. 32 Deneau DG, Wood GS, Beckstead J, et al: Woringer-Kolopp disease (pagetoid reticulosis): Four cases with histopathologic, ultrastructural, and immunohistologic observations. Arch Dermatol 1984; 120: 1045– 1051. 33 Wood GS, Weiss LM, Hu CH, et al: T-cell antigen deficiencies and clonal rearrangements of T-cell receptor genes in pagetoid reticulosis (Woringer Kolopp Disease). N Engl J Med 1988; 318: 164– 167. 34 Kardashian JL, Zackheim HS, Egbert BM: Lymphomatoid papulosis associated with plaque-stage and granulomatous mycosis fungoides. Arch Dermatol 1985; 121: 1175– 1180. 35 Nickoloff BJ, Wood C: Benign idiopathic versus mycosis fungoides-associated follicular mucinosis. Pediatr Dermatol 1985; 2: 201– 206. 36 Toonstra J, Henquet CJ, van Weelden HV, et al: Actinic reticuloid: A clinical, photobiologic, histopathologic, and follow-up study of 16 patients. J Am Acad Dermatol 1989; 21: 205– 214. 37 Bunn PA, Lamberg SI: Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 725– 728. 38 Lever WF, Lever GS: Histopathology of the Skin, ed 7. Philadelphia, JB Lippincott Company, 1990. 39 Ackerman AB: Histologic Diagnosis of Inflammatory Skin Diseases. Malvern, Pennsylvania, Lea and Febiger, 1978. 40 Nickoloff BJ, Wood C: Benign idiopathic versus mycosis fungoides-associated follicular mucinosis. Pediatr Dermatol 1985; 2: 201– 266. 41 Sentis HI, Willemze R, Scheffer E: Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: A comparison with benign forms of erythroderma. J Am Acad Dermatol 1986; 15: 1217– 1226. 42 Buechner SA, Winkelmann RK: Sézary syndrome: A clinicopathologic study of 39 cases. Arch Dermatol 1983; 119: 979– 986. 43 The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112– 2135. 44 Suchi T, Lennert K, Tu LY, et al: Histopathology and immunohistochemistry of peripheral T-cell lymphomas: A proposal for their classification. J Clin Pathol 1987; 40: 995– 1015. 45 Dmitrovsky E, Matthews MJ, Bunn PA, et al: Cytologic transformation in cutaneous T-cell lymphoma: A clinicopathologic entity associated with poor prognosis. J Clin Oncol 1987; 5: 208– 215. 46 Sausville EA, Eddy JL, Makuch RW, et al: Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome: Definition of three distinctive prognostic groups. Ann Intern Med 1988; 109: 372– 382. 47 Lutzner MA, Edelson RL, Schein P, et al: Cutaneous T-cell lymphomas: The Sézary syndrome, mycosis fungoides and related disorders. Ann Intern Med 1975; 83: 534– 552. 48 Meijer CJLM, van der Loo EM, van Vloten WA, et al: Early diagnosis of mycosis fungoides and Sézary syndrome by morphometric analysis of lymphoid cells in the skin. Cancer 1980; 45: 2864– 2871. 49 Willemze R, Cornelisse CJ, Hermans J, et al: Quantitative electron microscopy in the early diagnosis of cutaneous T-cell lymphomas: A long-term follow-up study of 77 patients. Am J Pathol 1986; 123: 166– 173. 50 Fletcher V, Zackheim HS, Beckstead JH: Circulating Sézary cells: A new preparatory method for their identification and enumeration. Arch Pathol Lab Med 1984; 108: 954– 958. 51 Whang-Peng J, Bunn PA Jr, Knutsen T, et al: Clinical implications of cytogenetic studies in cutaneous T-cell lymphoma (CTCL). Cancer 1982; 50: 1539– 1553. 52 Edelson RL, Berger CL, Raafat J, Warburton D: Karyotype studies of cutaneous T-cell lymphoma: Evidence for clonal origin. J Invest Dermatol 1979; 73: 548– 550. 53 Erkman-Balis B, Rappaport H: Cytogenetic studies in mycosis fungoides. Cancer 1974; 34: 626– 633. 54 Bunn PA Jr, Huberman MS, Whang-Peng J, et al: Prospective staging evaluation of patients with cutaneous T-cell lymphomas: Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med 1980; 93: 223– 230. 55 Koduru PR, Filippa DA, Richardson ME, et al: Cytogenetic and histologic correlations in malignant lymphoma. Blood 1987; 69: 97– 102. 56 Raimondi SC, Pui C, Behm FG, Williams DL: 7q32-q36 translocations in childhood T-cell leukemia: Cytogenetic evidence for involvement of the T-cell receptor beta-chain gene. Blood 1987; 69: 131– 134. 57 Van Vloten WA, Schaberg A, van der Ploeg M: Cytophotometric studies on mycosis fungoides and other cutaneous reticuloses. Bull Cancer 1977; 64: 249– 258. 58 Van Vloten WA, Scheffer E, Meijer CJLM: DNA cytophotometry of lymph node imprints from patients with mycosis fungoides. J Invest Dermatol 1979; 73: 275– 277. 59 Wood GS, Weiss LM, Warnke RA, Sklar J: The immunopathology of cutaneous lymphomas: Immunophenotypic and immunogenotypic characteristics. Seminars Dermatol 1986; 5: 334– 345. 60 Michie SA, Abel EA, Hoppe RT, et al: Expression of T-cell receptor antigens in mycosis fungoides and inflammatory skin lesions. J Invest Dermatol 1989; 93: 116– 120. 61 Michie SA, Abel EA, Hoppe RT, et al: Discordant expression of antigens between intraepidermal and intradermal T-cells in mycosis fungoides. Am J Pathol 1990; 137: 1447– 1451. 62 Wood GS, Hong SR, Sasaki DT, et al: Leu-8/CD7 antigen expression by CD3 + T-cells: Comparative analysis of skin and blood in mycosis fungoides/Sézary syndrome relative to normal blood values. J Am Acad Dermatol 1990; 22: 602– 607. 63 Weiss LM, Hu E, Wood GS, et al: Clonal rearrangements of T-cell receptor genes in mycosis fungoides and dermatopathic lymphadenopathy. N Engl J Med 1985; 313: 539– 544. 64 Weiss LM, Wood GS, Hu E, et al: Detection of clonal T-cell receptor gene rearrangements in the peripheral blood of patients with mycosis fungoides/Sézary syndrome. J Invest Dermatol 1989; 92: 601– 604. 65 Dosaka N, Tanaka T, Fujita M, et al: Southern blot analysis of clonal rearrangements of T-cell receptor gene in plaque lesion of mycosis fungoides. J Invest Dermatol 1989; 93: 626– 629. 66 Ralfkiaer E, O'Conner NT, Crick J, et al: Genotypic analysis of cutaneous T-cell lymphomas. J Invest Dermatol 1987; 88: 762– 765. 67 Zelickson BD, Peters MS, Muller SA, et al: Study of T-cell receptor gene rearrangements in cutaneous T-cell lymphoma, parapsoriasis, and benign dermatoses. J Cutan Pathol 1989; 16:331. 68 Lessin SR, Rook AH, Rovera G: Molecular diagnosis of cutaneous T-cell lymphoma: Polymerase chain reaction amplification of T-cell antigen receptor beta-chain gene rearrangements. J Invest Dermatol 1991; 96: 299– 302. 69 Farber EM, Zackheim HS, Cox AJ, et al: Treatment of mycosis fungoides. Arch Dermatol 1968; 97: 165– 172. 70 Van Scott EJ, Kalmanson JD: Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2): Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunological tolerance. Cancer 1973; 32: 18– 30. 71 Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A: Topical mechlorethamine therapy for early stage mycosis fungoides. J Am Acad Dermatol 1988; 19: 684– 691. 72 Price NM, Hoppe RT, Deneau DG: Ointment-based mechlorethamine treatment for mycosis fungoides. Cancer 1983; 52: 2214– 2219. 73 Hoppe RT, Abel EA, Deneau DG, Price NM: Mycosis fungoides: Management with topical nitrogen mustard. J Clin Oncol 1987; 5: 1796– 1803. 74 Vonderheid EC, Tan ET, Kantor AF, et al: Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 416– 428. 75 Hoppe RT, Wood GS, Abel EA: Mycosis fungoides and the Sézary syndrome: Pathology, staging, and treatment. Curr Probl Cancer 1990; 14: 293– 371. 76 Price NM, Constantine VS, Hoppe RT, et al: Topical mechlorethamine therapy for mycosis fungoides. Br J Dermatol 1977; 97: 547– 550. 77 Waldorf DS, Haynes HA, Van Scott EJ: Cutaneous hypersensitivity and desensitization to mechlorethamine in patients with mycosis fungoides lymphoma. Ann Intern Med 1967; 67: 282– 290. 78 Constantine VS, Fuks ZY, Farber EM: Mechlorethamine desensitization in therapy for mycosis fungoides: Topical desensitization to mechlorethamine (nitrogen mustard) contact hypersensitivity. Arch Dermatol 1975; 111: 484– 488. 79 Abel EA, Sendagorta E, Hoppe RT: Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. J Am Acad Dermatol 1986; 14: 1029– 1038. 80 Zackheim HS, Epstein EH, Crain WR: Topical carmustine (BCNU) for cutaneous T-cell Lymphoma: A 15-year experience in 143 patients. J Am Acad Dermatol 1990; 22: 802– 810. 81 Kim JH, Nisce LZ, D'Anglo GJ: Dose-time fractionation study in patients with mycosis fungoides and lymphoma cutis. Radiology 1976; 119: 439– 442. 82 Karzmark CJ, Loevinger R, Steele RE, et al: A technique for large-field, superficial electron therapy. Radiology 1960; 74: 633– 644. 83 Page V, Gardner A, Karzmark CJ: Patient dosimetry in the electron treatment of large superficial lesions. Radiology 1970; 94: 635– 641. 84 Cox RS, Heck RJ, Fessenden P, et al: Development of total-skin electron therapy at two energies. Int J Radiat Oncol Biol Phys 1990; 18: 659– 669. 85 Spittle MF: Mycosis fungoides: Electron-beam therapy in England. Cancer Treat Rep 1979; 63: 639– 641. 86 Nisce LZ, Safai B, Kim JH: Effectiveness of once weekly total skin electron-beam therapy in mycosis fungoides and Sézary syndrome. Cancer 1981; 47: 870– 876. 87 Hamminga B, Noordijk EM, van Vloten WA: Treatment of mycosis fungoides: Total-skin electron-beam irradiation vs topical mechlorethamine therapy. Arch Dermatol 1982; 118: 150– 153. 88 Tadros AA, Tepperman BS, Hryniuk WM, et al: Total skin electron irradiation for mycosis fungoides: Failure analysis and prognostic factors. Int J Radiat Oncol Biol Phys 1983; 9: 1279– 1287. 89 Van Vloten WA, De Vroome H, Noordijk EM: Total skin electron beam irradiation for cutaneous T-cell lymphoma (mycosis fungoides). Br J Dermatol 1985; 112: 697– 702. 90 Desai KR, Pezner RD, Lipsett JA, et al: Total skin electron irradiation for mycosis fungoides: Relationship between acute toxicities and measured dose at different anatomic sites. Int J Radiat Oncol Biol Phys 1988; 15: 641– 645. 91 Hoppe RT, Fuks Z, Bagshaw MA: Radiation therapy in the management of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 625– 632. 92 Price NM, Hoppe RT, Constantine VS, et al: The treatment of mycosis fungoides: Adjuvant topical mechlorethamine after electron beam therapy. Cancer 1977; 40: 2851– 2853. 93 Gilchrest BA, Parrish JA, Tanenbaum L, et al: Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976; 38: 683– 689. 94 Stern RS, et al: Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156– 1161. 95 Stern RS, Abel EA, Wintroub B, et al: Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation. N Engl J Med 1990; 322: 1093– 1097. 96 Stern RS, Parrish JA, Fitzpatrick TB: Ocular findings in patients treated with PUVA. J Invest Dermatol 1985; 85: 269– 273. 97 Abel EA, Deneau DG, Farber EM, et al: PUVA treatment of erythrodermic and plaque-type mycosis fungoides. J Am Acad Dermatol 1981; 4: 423– 429. 98 Roenigk HH Jr: Photochemotherapy for mycosis fungoides: Long-term follow-up study. Cancer Treat Rep 1979; 63: 669– 673. 99 Briffa DV, Warin AP, Harrington CI, Bleehen SS: Photochemotherapy in mycosis fungoides: A study of 73 patients. Lancet 1980; 2: 49– 53. 100 Gilchrest BA: Methoxsalen photochemotherapy for mycosis fungoides. Cancer Treat Rep 1979; 63: 663– 667. 101 Lowe NJ, Cripps DJ, Dufton PA, Vickers CF: Photochemotherapy for mycosis fungoides: A clinical and histological study. Arch Dermatol 1979; 115: 50– 53. 102 Rosenbaum MM, Roenigk HH, Caro WA, et al: Photochemotherapy in cutaneous T cell lymphoma and parapsoriasis en plaques: Long-term follow-up in forty-three patients. J Am Acad Dermatol 1985; 13: 613– 622. 103 Hönigsmann H, Brenner W, Rauschmeier W, et al: Photochemotherapy for cutaneous T cell lymphoma: A follow-up study. J Am Acad Dermatol 1984; 10: 238– 245. 104 Abel EA, Sendagorta E, Hoppe RT, Hu CH: PUVA treatment of erythrodermic and plaque-type mycosis fungoides: 10-year follow-up study. Arch Dermatol 1987; 123: 897– 901. 105 Kessler JF, Meyskens FL Jr, Levine N, et al: Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet 1983; 1: 1345– 1347. 106 Claudy AL, Rouchouse B, Boucheron S, Le Petit JC: Treatment of cutaneous lymphoma with etretinate. Br J Dermatol 1983; 109: 49– 56. 107 Edelson R, Berger C, Gasparro F, et al: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: Preliminary results. N Engl J Med 1987; 316: 297– 303. 108 Miller RA, Oseroff AR, Stratte PT, et al: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 1983; 62: 988– 995. 109 Winklemann RK, Diaz-Perez JL, Buechner SA: The treatment of Sézary syndrome. J Am Acad Dermatol 1984; 10: 1000– 1004. 110 Zackheim HS, Epstein EH: Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 1989; 21: 757– 762. 111 Wieselthier JS, Koh HK: Sézary syndrome: Diagnosis, prognosis, and critical review of treatment options. J Am Acad Dermatol 1990; 22: 381– 401. 112 Broder S, Bunn PA Jr: Cutaneous T-cell lymphomas. Semin Oncol 1980; 7: 310– 331. 113 Bunn PA, Ihde DC, Foon KA: The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986; 57: 1689– 1695. 114 Olsen EA, Rosen ST, Vollmer RT, et al: Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 395– 407. 115 Kuzel TM, Gilyon K, Springer E, et al: Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990; 82: 203– 207. 116 Knox SJ, Levy R, Hodgkinson S, et al: Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991; 77: 20– 30. 117 Merlo CJ, Hoppe RT, Abel E, Cox RS: Extra-cutaneous mycosis fungoides. Cancer 1987; 60: 397– 402. 118 Axelrod PI, Lorber B, Vonderheid, EC: Infections complicating mycosis fungoides and Sézary syndrome. JAMA 1992; 267: 1354– 1358. Citing Literature Volume43, Issue2March/April 1993Pages 93-115 ReferencesRelatedInformation
Referência(s)